Latest stories on XNCR
Xencor price target raised to $35 from $27 at Barclays
The Fly64 · neutralanalyst
Xencor price target raised to $21 from $14 at JPMorgan
The Fly61 · neutralanalyst
Xencor to Present at the 2026 Cantor Global Healthcare Conference
StockTitan56 · neutralgeneral
Xencor price target raised to $46 from $40 at Raymond James
The Fly63 · neutralanalyst
Xencor Reports Second Quarter 2026 Financial Results
StockTitan50 · neutralgeneral
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch
TipRanks63 · neutralproduct/pr
Xencor Inc (XNCR) files 8-K
SEC 8-K50 · neutralgeneral
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
StockTitan59 · neutralgeneral
Xencor's XmAb819 Heads to ESMO 2026: Phase 1 Data to Inform Pivotal Study in Clear Cell Renal Cell Carcinoma
MarketChameleon67 · bullishproduct/pr
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data
Seeking Alpha73 · bullishproduct/pr
Xencor advances 17% after revealing ESMO 2026 oral presentation slot
Seeking Alpha73 · bullishproduct/pr
Xencor: Bullish On Their Increasingly In-House Pipeline
Seeking Alpha63 · neutralproduct/pr
Xencor Inc (XNCR) files 8-K
SEC 8-K50 · neutralgeneral
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Seeking Alpha73 · bullishproduct/pr